Works by Flaherty, Keith

Results: 126
    1
    2
    3

    Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.

    Published in:
    Nature Medicine, 2012, v. 18, n. 12, p. 1857, doi. 10.1038/nm1212-1857a
    By:
    • Kwong, Lawrence N;
    • Costello, James C;
    • Liu, Huiyun;
    • Jiang, Shan;
    • Helms, Timothy L;
    • Langsdorf, Aliete E;
    • Jakubosky, David;
    • Genovese, Giannicola;
    • Muller, Florian L;
    • Jeong, Joseph H;
    • Bender, Ryan P;
    • Chu, Gerald C;
    • Flaherty, Keith T;
    • Wargo, Jennifer A;
    • Collins, James J;
    • Chin, Lynda
    Publication type:
    Article
    4

    Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.

    Published in:
    Nature Medicine, 2012, v. 18, n. 10, p. 1503, doi. 10.1038/nm.2941
    By:
    • Kwong, Lawrence N;
    • Costello, James C;
    • Liu, Huiyun;
    • Jiang, Shan;
    • Helms, Timothy L;
    • Langsdorf, Aliete E;
    • Jakubosky, David;
    • Genovese, Giannicola;
    • Muller, Florian L;
    • Jeong, Joseph H;
    • Bender, Ryan P;
    • Chu, Gerald C;
    • Flaherty, Keith T;
    • Wargo, Jennifer A;
    • Collins, James J;
    • Chin, Lynda
    Publication type:
    Article
    5

    The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

    Published in:
    Nature Genetics, 2015, v. 47, n. 3, p. 250, doi. 10.1038/ng.3218
    By:
    • Lin, Luping;
    • Chan, Elton;
    • Olivas, Victor;
    • Cade, Lindsay;
    • Pazarentzos, Evangelos;
    • Asthana, Saurabh;
    • Neel, Dana;
    • Yan, Jenny Jiacheng;
    • Lu, Xinyuan;
    • Pham, Luu;
    • Wang, Mingxue M;
    • Collisson, Eric A;
    • Algazi, Alain;
    • Bivona, Trever G;
    • Muñoz-Couselo, Eva;
    • Cortes, Javier;
    • Frederick, Dennie T;
    • Flaherty, Keith T;
    • Cooper, Zachary A;
    • Wargo, Jennifer A
    Publication type:
    Article
    6
    7
    8

    STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming.

    Published in:
    Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-29541-9
    By:
    • Chu, Zhaowei;
    • Gu, Lei;
    • Hu, Yeguang;
    • Zhang, Xiaoyang;
    • Li, Man;
    • Chen, Jiajia;
    • Teng, Da;
    • Huang, Man;
    • Shen, Che-Hung;
    • Cai, Li;
    • Yoshida, Toshimi;
    • Qi, Yifeng;
    • Niu, Zhixin;
    • Feng, Austin;
    • Geng, Songmei;
    • Frederick, Dennie T.;
    • Specht, Emma;
    • Piris, Adriano;
    • Sullivan, Ryan J.;
    • Flaherty, Keith T.
    Publication type:
    Article
    9
    10
    11

    Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

    Published in:
    Science Signaling, 2014, v. 7, n. 357, p. 1, doi. 10.1126/scisignal.aaa1877
    By:
    • Martz, Colin A.;
    • Ottina, Kathleen A.;
    • Singleton, Katherine R.;
    • Jasper, Jeff S.;
    • Wardell, Suzanne E.;
    • Peraza-Penton, Ashley;
    • Anderson, Grace R.;
    • Winter, Peter S.;
    • Tim Wang;
    • Alley, Holly M.;
    • Kwong, Lawrence N.;
    • Cooper, Zachary A.;
    • Tetzlaff, Michael;
    • Pei-Ling Chen;
    • Rathmell, Jeffrey C.;
    • Flaherty, Keith T.;
    • Wargo, Jennifer A.;
    • McDonnell, Donald P.;
    • Sabatini, David M.;
    • Wood, Kris C.
    Publication type:
    Article
    12

    Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting <i>De Novo</i> Resistance Using BH3 Mimetics.

    Published in:
    PLoS ONE, 2014, v. 9, n. 7, p. 1, doi. 10.1371/journal.pone.0101286
    By:
    • Frederick, Dennie T.;
    • Salas Fragomeni, Roberto A.;
    • Schalck, Aislyn;
    • Ferreiro-Neira, Isabel;
    • Hoff, Taylor;
    • Cooper, Zachary A.;
    • Haq, Rizwan;
    • Panka, David J.;
    • Kwong, Lawrence N.;
    • Davies, Michael A.;
    • Cusack, James C.;
    • Flaherty, Keith T.;
    • Fisher, David E.;
    • Mier, James W.;
    • Wargo, Jennifer A.;
    • Sullivan, Ryan J.
    Publication type:
    Article
    13

    An Active Learning Approach for Rapid Characterization of Endothelial Cells in Human Tumors.

    Published in:
    PLoS ONE, 2014, v. 9, n. 3, p. 1, doi. 10.1371/journal.pone.0090495
    By:
    • Padmanabhan, Raghav K.;
    • Somasundar, Vinay H.;
    • Griffith, Sandra D.;
    • Zhu, Jianliang;
    • Samoyedny, Drew;
    • Tan, Kay See;
    • Hu, Jiahao;
    • Liao, Xuejun;
    • Carin, Lawrence;
    • Yoon, Sam S.;
    • Flaherty, Keith T.;
    • DiPaola, Robert S.;
    • Heitjan, Daniel F.;
    • Lal, Priti;
    • Feldman, Michael D.;
    • Roysam, Badrinath;
    • Lee, William M. F.
    Publication type:
    Article
    14
    15
    16

    A Melanoma Molecular Disease Model.

    Published in:
    PLoS ONE, 2011, v. 6, n. 3, p. 1, doi. 10.1371/journal.pone.0018257
    By:
    • Vidwans, Smruti J.;
    • Flaherty, Keith T.;
    • Fisher, David E.;
    • Tenenbaum, Jay M.;
    • Travers, Michael D.;
    • Shrager, Jeff
    Publication type:
    Article
    17
    18
    19
    20

    Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.

    Published in:
    Cancer (0008543X), 2014, v. 120, n. 1, p. 77, doi. 10.1002/cncr.28294
    By:
    • Ciunci, Christine A.;
    • Perini, Rodolfo F.;
    • Avadhani, Anjali N.;
    • Kang, Hyunseon C.;
    • Sun, Weijing;
    • Redlinger, Maryann;
    • Harlacker, Kathleen;
    • Flaherty, Keith T.;
    • Giantonio, Bruce J.;
    • Rosen, Mark A.;
    • Divgi, Chaitanya R.;
    • Song, Hee Kwon;
    • Englander, Sarah;
    • Troxel, Andrea;
    • Schnall, Mitchell;
    • O'Dwyer, Peter J.
    Publication type:
    Article
    21

    Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

    Published in:
    2013
    By:
    • Luke, Jason J;
    • Callahan, Margaret K;
    • Postow, Michael A;
    • Romano, Emanuela;
    • Ramaiya, Nikhil;
    • Bluth, Mark;
    • Giobbie-Hurder, Anita;
    • Lawrence, Donald P;
    • Ibrahim, Nageatte;
    • Ott, Patrick A;
    • Flaherty, Keith T;
    • Sullivan, Ryan J;
    • Harding, James J;
    • D'Angelo, Sandra;
    • Dickson, Mark;
    • Schwartz, Gary K;
    • Chapman, Paul B;
    • Wolchok, Jedd D;
    • Hodi, F Stephen;
    • Carvajal, Richard D
    Publication type:
    journal article
    22

    Clinical Activity of Ipilimumab for Metastatic Uveal Melanoma.

    Published in:
    Cancer (0008543X), 2013, v. 119, n. 20, p. 3687, doi. 10.1002/cncr.28282
    By:
    • Luke, Jason J.;
    • Callahan, Margaret K.;
    • Postow, Michael A.;
    • Romano, Emanuela;
    • Ramaiya, Nikhil;
    • Bluth, Mark;
    • Giobbie‐Hurder, Anita;
    • Lawrence, Donald P.;
    • Ibrahim, Nageatte;
    • Ott, Patrick A.;
    • Flaherty, Keith T.;
    • Sullivan, Ryan J.;
    • Harding, James J.;
    • D'Angelo, Sandra;
    • Dickson, Mark;
    • Schwartz, Gary K.;
    • Chapman, Paul B.;
    • Wolchok, Jedd D.;
    • Hodi, F. Stephen;
    • Carvajal, Richard D.
    Publication type:
    Article
    23
    24

    BRAF, a Target in Melanoma.

    Published in:
    Cancer (0008543X), 2010, v. 116, n. 21, p. 4902, doi. 10.1002/cncr.25261
    By:
    • Flaherty, Keith T.;
    • McArthur, Grant
    Publication type:
    Article
    25
    26

    POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.

    Published in:
    Neuro-Oncology Advances, 2024, v. 6, n. 1, p. 1, doi. 10.1093/noajnl/vdae033
    By:
    • Menzies, Alexander M;
    • Long, Georgina V;
    • Kohn, Amiee;
    • Tawbi, Hussein;
    • Weber, Jeffrey;
    • Flaherty, Keith;
    • McArthur, Grant A;
    • Ascierto, Paolo A;
    • Pfluger, Yanina;
    • Lewis, Karl;
    • Tsai, Katy K;
    • Hamid, Omid;
    • Prenen, Hans;
    • Fein, Luis;
    • Wang, Erjian;
    • Guenzel, Carolin;
    • Zhang, Fan;
    • Kleha, Joseph F;
    • Pietro, Alessandra di;
    • Davies, Michael A
    Publication type:
    Article
    27
    28
    29

    Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.

    Published in:
    2016
    By:
    • Sabbatino, Francesco;
    • Yangyang Wang;
    • Scognamiglio, Giosue;
    • Favoino, Elvira;
    • Feldman, Steven A.;
    • Villani, Vincenzo;
    • Flaherty, Keith T.;
    • Nota, Sjoerd;
    • Giannarelli, Diana;
    • Simeone, Ester;
    • Anniciello, Anna M.;
    • Palmieri, Giuseppe;
    • Pepe, Stefano;
    • Botti, Gerardo;
    • Ascierto, Paolo A.;
    • Ferrone, Cristina R.;
    • Ferrone, Soldano;
    • Wang, Yangyang;
    • Scognamiglio, Giosuè
    Publication type:
    journal article
    30
    31

    Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network (ECOG‐ACRIN) E2805.

    Published in:
    BJU International, 2022, v. 129, n. 6, p. 718, doi. 10.1111/bju.15587
    By:
    • Karam, Jose A.;
    • Puligandla, Maneka;
    • Flaherty, Keith T.;
    • Uzzo, Robert G.;
    • Matin, Surena F.;
    • Pins, Michael R.;
    • Wood, Christopher G.;
    • Kane, Christopher;
    • Jewett, Michael A. S.;
    • Kim, Se Eun;
    • Dutcher, Janice P.;
    • DiPaola, Robert S.;
    • Haas, Naomi B.
    Publication type:
    Article
    32

    Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

    Published in:
    2023
    By:
    • Boshuizen, Julia;
    • Vredevoogd, David W.;
    • Krijgsman, Oscar;
    • Ligtenberg, Maarten A.;
    • Blankenstein, Stephanie;
    • de Bruijn, Beaunelle;
    • Frederick, Dennie T.;
    • Kenski, Juliana C. N.;
    • Parren, Mara;
    • Brüggemann, Marieke;
    • Madu, Max F.;
    • Rozeman, Elisa A.;
    • Song, Ji-Ying;
    • Horlings, Hugo M.;
    • Blank, Christian U.;
    • van Akkooi, Alexander C. J.;
    • Flaherty, Keith T.;
    • Boland, Genevieve M.;
    • Peeper, Daniel S.
    Publication type:
    Correction Notice
    33

    Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells.

    Published in:
    Science Signaling, 2013, v. 6, n. 260, p. 1, doi. 10.1126/scisignal.2003057
    By:
    • Beck, Daniela;
    • Niessner, Heike;
    • Smalley, Keiran S. M.;
    • Flaherty, Keith;
    • Paraiso, Kim H. T.;
    • Busch, Christian;
    • Sinnberg, Tobias;
    • Vasseur, Sophie;
    • Iovanna, Juan Lucio;
    • Drießen, Stefan;
    • Stork, Björn;
    • Wesselborg, Sebastian;
    • Schaller, Martin;
    • Biedermann, Tilo;
    • Bauer, Jürgen;
    • Lasithiotakis, Konstantinos;
    • Weide, Benjamin;
    • Eberle, Jürgen;
    • Schittek, Birgit;
    • Schadendorf, Dirk
    Publication type:
    Article
    34
    35

    Hyperspectral imaging.

    Published in:
    Cancer Biology & Therapy, 2011, v. 12, n. 4, p. 326, doi. 10.4161/cbt.12.4.17142
    By:
    • Dicker, David T.;
    • Kahn, Nadia;
    • Flaherty, Keith T.;
    • Lerner, Jeremy;
    • El-Deiry, Wafik S.
    Publication type:
    Article
    36
    37
    38

    Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.

    Published in:
    Molecular Systems Biology, 2019, v. 15, n. 3, p. N.PAG, doi. 10.15252/msb.20188323
    By:
    • Park, Seung Gu;
    • Sahu, Avinash Das;
    • Ponomarova, Olga;
    • Jerby‐Arnon, Livnat;
    • Wagner, Allon;
    • Miao, Benchun;
    • Friedman, Adam A;
    • Amzallag, Arnaud;
    • Moll, Tabea;
    • Kasumova, Gyulnara;
    • Greninger, Patricia;
    • Egan, Regina K;
    • Damon, Leah J;
    • Frederick, Dennie T;
    • Boland, Genevieve;
    • Benes, Cyril;
    • Flaherty, Keith;
    • Cheng, Kuoyuan;
    • Robinson, Welles;
    • Hannenhalli, Sridhar
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46
    47

    Vemurafenib.

    Published in:
    2011
    By:
    • Flaherty, Keith. T;
    • Yasothan, Uma;
    • Kirkpatrick, Peter
    Publication type:
    journal article
    48

    Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.

    Published in:
    Scientific Reports, 2017, p. 44123, doi. 10.1038/srep44123
    By:
    • Chen, Yunching;
    • Liu, Ya-Chi;
    • Sung, Yun-Chieh;
    • Ramjiawan, Rakesh R.;
    • Lin, Ts-Ting;
    • Chang, Chih-Chun;
    • Jeng, Kuo-Shyang;
    • Chang, Chiung-Fang;
    • Liu, Chun-Hung;
    • Gao, Dong-Yu;
    • Hsu, Fu-Fei;
    • Duyverman, Annique M.;
    • Kitahara, Shuji;
    • Huang, Peigen;
    • Dima, Simona;
    • Popescu, Irinel;
    • Flaherty, Keith T.;
    • Zhu, Andrew X.;
    • Bardeesy, Nabeel;
    • Jain, Rakesh K.
    Publication type:
    Article
    49
    50

    Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010".

    Published in:
    2011
    By:
    • Ascierto, Paolo A.;
    • De Maio, Eleonora;
    • Bertuzzi, Stefano;
    • Palmieri, Giuseppe;
    • Halaban, Ruth;
    • Hendrix, Mary;
    • Kashani-sabet, Mohamed;
    • Ferrone, Soldano;
    • Ena Wang;
    • Cochran, Alistair;
    • Rivoltini, Licia;
    • Lee, Peter P.;
    • Fox, Bernard A.;
    • Kirkwood, John M.;
    • Ullmann, Claudio Dansky;
    • Lehmann, Frederic F.;
    • Sznol, Mario;
    • Schwartzentruber, Douglas J.;
    • Maio, Michele;
    • Flaherty, Keith
    Publication type:
    research